News

A posthoc analysis of the EMPEROR-Preserved trial suggested empagliflozin decreased the risk of heart failure hospitalization or cardiovascular death, regardless of background diuretic status.

Key opinion leaders at ATS 2023 urge physicians to treat more than just symptoms in patients with COPD and consider mood disorders and cardiac comorbidities.

The podcast will explore the personal experiences of people living with rheumatic diseases and the latest research evidence that informs their diagnosis and treatment.

As a follow-up to an episode earlier this year and the FDA clearances of the technology that forms the iLet Bionic Pancreas, hosts sat down in the MJH Life Sciences studio for a special edition recording to explore the implications of the clearance, dispel misconceptions surrounding the system, and hypothesize about the future of this technology in people with diabetes.

Research into global prevalence rates of autoimmune conditions such as multiple sclerosis and psoriasis highlights important information for future research and medical resource allocation.

A beta diversity analyses revealed a distinct clustering pattern between healthy controls and patients with HBV-related liver disease and the composition of bacteria from the phylum level to the genus level varies across the stages of liver disease.

These findings suggest that disparities in reporting data may be present in nursing homes, with implications for surveillance of nursing homes, priority setting for facilities, as well as payment and research.

The results show a moderate certainty on the lack of effect across outcomes and 2 values and preferences studies found participants enjoyed specific counseling behavioral interventions.

Ahead of the May 27, 2023 PDUFA date, the HCPLive Cardiology editorial team spoke to a group of cardiologists to capture their perspective of the potential role of sotagliflozin.

Lungcast hits the road, as the director of pulmonary and critical care medicine at University of Vermont joins to discuss ATS 2023 headlines and the Airways Clinical Research Network.

The findings could provide insight into incorporating both OCTA and artificial intelligence for early detection of DMI and better enhancing the management of diabetic retinopathy.

Janssen aims to address health inequities and promote culturally competent care.

At ATS 2023, Dr. Galiatsatos illuminates what makes lung cancer screening different and how the screening approach is changing.

An analysis of the UK Biobank found menstrual cycles less than 21 days or longer than 35 days were associated with a 19% higher risk of CVD compared with a regular menstrual cycle length.

Individuals who sought outpatient mental health and addiction services were generally younger, proportionately more female, more likely to have a psychiatric comorbidity, and more likely to have had their index alcohol-related hospitalization attributed to than to other diagnoses such as harmful alcohol use or alcoholic liver disease.

Data from the open-label extension period of the APOLLO-B trial provide new insight into the benefits of patisiran in patients with ATTR amyloidosis with cardiomyopathy.

New data indicates that increased risk for offspring in developing different disorders is associated with maternal alopecia areata exposure, expanding the available information on alopecia and maternal autoimmunity.

There was an association between NAFLD in the South-Asian population and diabetes mellitus, hypertension, dyslipidemia, general obesity, central obesity and metabolic syndrome.

An analysis of data from the ARIC study is offering new insight into the impact of age at diabetes onset on the risk of developing dementia later in life.

This study examined survival of brodalumab after switching from ixekizumab, providing more information on real-world, non-medical switching for patients with psoriasis.

In an interview at ATS 2023, Dr. Rutland stresses the importance of studying the immune system's response to various diseases, emphasizing the potential impact of pipeline molecules.

The disparities compelled them to launch Determi-Nation, which utilizes healthcare providers, advocates, and patients within the psoriatic disease community to co-create solutions that address the observed inequities.

A post hoc analysis shows benralizumab was even more efficacious in patients with concomitant nasal polyps at both 6 and 12 months.

Dr. Panagis Galiatsatos explains the new lung cancer screening aims to address the disparities of disease onset and progression across different racial populations.

Phase 2 data suggest the oral small-molecule GLP-1R agonist reduced HbA1c at all dose levels studied and reduced body weight at doses of ≥80 mg twice daily compared with placebo in adults with T2D.

Though still not in abundance on the market, ICS/LAMA/LABA triple-therapy single inhaler treatment options are becoming more valued for COPD exacerbation and comorbid disease risk.

An analysis of the phase 3 NAVIGATOR trial shows tezepelumab did not provide differing efficacy among men and women, despite historic trends of disparate severe asthma outcomes among sexes.

The approval was based on a comprehensive assortment of studies which showed adalimumab-aaty was comparable to the reference product, adalimumab.

In this episode, Veeral Sheth, MD, sits down with Jay Duker, MD for a discussion on his storied career, fostering relationships with industry, and the current technology being worked on at Eyepoint Pharmaceuticals for retinal disorders.

New data indicates the usefulness of spironolactone as an alternative to oral antibiotics for women in the UK with acne vulgaris, given increasing resistance to antibiotics due to widespread use.